Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBITDA (2019 - 2025)

Historic EBITDA for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.9 million.

  • Benitec Biopharma's EBITDA fell 8689.55% to -$8.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$37.9 million, marking a year-over-year decrease of 7358.46%. This contributed to the annual value of -$37.9 million for FY2025, which is 7358.46% down from last year.
  • As of Q2 2025, Benitec Biopharma's EBITDA stood at -$8.9 million, which was down 8689.55% from -$14.5 million recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's EBITDA peaked at -$3.5 million during Q1 2022, and registered a low of -$14.5 million during Q1 2025.
  • Moreover, its 5-year median value for EBITDA was -$4.8 million (2021), whereas its average is -$5.8 million.
  • As far as peak fluctuations go, Benitec Biopharma's EBITDA surged by 1260.16% in 2024, and later crashed by 24908.7% in 2025.
  • Quarter analysis of 5 years shows Benitec Biopharma's EBITDA stood at -$4.9 million in 2021, then fell by 14.21% to -$5.6 million in 2022, then fell by 25.11% to -$7.0 million in 2023, then tumbled by 32.67% to -$9.2 million in 2024, then grew by 3.45% to -$8.9 million in 2025.
  • Its EBITDA was -$8.9 million in Q2 2025, compared to -$14.5 million in Q1 2025 and -$9.2 million in Q4 2024.